ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
HanAll Biopharma Reports Second Quarter 2021 Results
July 29, 2021HanAll Biopharma announced today that the company had achieved sales of 23.4 billion won, operating profit of 1.6 billion won, and net profit of 3.3 billion won in the second quarter of 2021. -
HanAll Biopharma Reports First Quarter 2021 Financial Results
May 07, 2021HanAll Biopharma announced on the 29th, Apr. that it achieved 27.8 billion won in sales, 5.4 billion won in operating profit and 4.5 billion won in net profit in the first quarter of this year. -
Harbour BioMed to develop and commercialise HanAll’s biologic therapies in Greater China
September 14, 2017The deal includes HanAll Biopharma’s anti-Fc receptor (FcRn) monoclonal antibody, HL161, and anti-tumour necrosis factor (TNF) ophthalmic solution, HL036.
Pharma Sources Insight January 2025
